Medication info
Janumet XR Extended-Release Tablet 50/500 mg

Janumet XR Extended-Release Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tablet
Manufacturer / importer
Chong Kun Dang Pharm.
Appearance
Light blue, biconvex oval film-coated tablet with '78' engraved on one side.
Packaging
28 Tablets/Bottle, 56 Tablets/Bottle
Approval status
Active

MFDS item code 201309416 · Approved 2013.09.24 · Insurance code 655501780

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily with a meal, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently being treated with metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose of this drug is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients being treated with metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. - Patients currently taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start this drug at 2 tablets of 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with metformin combined with a sulfonylurea, metformin combined with insulin, or metformin combined with a thiazolidinedione: The initial dose of this drug is a total daily dose of sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this drug immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Importer
Chong Kun Dang Pharm.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to improve blood glucose control in patients with type 2 diabetes. When combined with dietary and exercise therapy, it helps manage blood glucose levels. The sitagliptin and metformin components work together to effectively lower blood glucose levels. It enhances blood control in patients to help prevent complications. Therefore, this medication has a positive effect on the treatment of type 2 diabetes and improves blood glucose control.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily with a meal, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently being treated with metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose of this drug is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients being treated with metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. - Patients currently taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start this drug at 2 tablets of 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with metformin combined with a sulfonylurea, metformin combined with insulin, or metformin combined with a thiazolidinedione: The initial dose of this drug is a total daily dose of sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this drug immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains sitagliptin and metformin and is used in the treatment of diabetes. However, serious hypersensitivity reactions may occur while taking this medication, so if signs of anaphylaxis, angioedema, or severe skin reactions appear, discontinue immediately and consult a doctor. There have also been reports of acute pancreatitis, so if symptoms such as abdominal pain, vomiting, or fever occur, notify healthcare personnel immediately. This medication should not be taken by patients with moderate to severe renal impairment or in unstable physical conditions such as acute heart failure or severe infections, and it should be discontinued before and after tests using iodinated contrast agents. It is safe for pregnant or breastfeeding women to avoid taking this medication. The risk of hypoglycemia exists with this medication, so blood glucose levels should be monitored carefully during irregular meals or vigorous exercise. Regular kidney function and blood tests should be conducted during treatment, especially for older patients or those with reduced kidney function. Additionally, the metformin component may rarely cause serious side effects such as lactic acidosis, so if symptoms such as abdominal pain, difficulty breathing, or lethargy occur, visit the hospital immediately. Avoid excessive alcohol intake during treatment, and it is important to inform healthcare personnel of all medications being taken due to potential interactions.

Side effects

  • Severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
Show 19 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • vitamin B12 deficiency
  • elevated liver enzymes
  • acute renal failure
  • severe hypoglycemia
  • peripheral edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is important to store this medication at a temperature between 1 and 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Light blue, biconvex oval film-coated tablet with '78' engraved on one side.

Package unit

28 Tablets/Bottle, 56 Tablets/Bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.